Welcome to the 20th WCP Virtual Congress Program Scheduling
The congress will officially run on Indochina Time (GMT+07:00)
To convert the congress times to your local time Click Here
Courses
Filter - Live Sessions: Plenary / Presidential Session | WPA TV | Original Sessions | Panel Discussions | Live Lecture in Thai | Special Sessions | Invited Symposia | Interorganizational Symposia | COVID-19 Live Sessions
Filter - Recorded Sessions: Accepted Symposia | Free Communications Sessions | Lectures in Thai | Special Lectures | State of the Art Symposia | COVID-19 Recorded Sessions
Displaying One Session
Industry Symposia B
Session Description
Persons affected by severe and persistent mental disorders (e.g., schizophrenia, mood disorders) exhibit significant illness-related morbidity often due to disturbances in motivation, depression, cognition and negative symptoms. Despite advances that have been made in psychopharmacology of these foregoing disorders most affected individuals do not have sufficient outcome due to inadequate response of the most disabling symptoms. A separate body of evidence indicates that D3 selective targeting may result in improvement in reward and cognitive-related symptoms which often appear clinically as amotivation, depression and negative symptoms. Herein, we review the rationale for targeting D3 and discuss potential therapeutic avenues for targeting D3 in a clinical setting.
How does D3/D2 partial agonists affect important clinical outcomes? (ID 3642)
Supported by Mitsubishi Tanabe Pharma (ID 3645)
Introduction and Presentation: Understanding the basics to sharpen your prescribing practice in the treatment of schizophrenia and mood disorders (ID 3749)
How does D3/D2 partial agonists affect important clinical outcomes? (ID 3750)
Live Q&A and Summary (ID 3751)